About this Research Topic
Therefore, great research efforts are focusing on the development and validation of novel effective assays to effectively detect HR status in OC. In addition, new compounds targeting HR and DDR actors beyond BRCA1 and BRCA2, are emerging to overcome or eventually prevent PARPi resistance. In this Research Topic, we mainly aim to discuss the current major evidence of the evolving role of HRD detection in OC patient selection. Additionally, we want to explore the HR-related mechanisms associated with PARPi resistance and the most promising strategies emerging to target them.
We welcome the submission of Original Research, Review, Mini Review, and Perspective Articles that cover, but are not limited to:
- Current HRD assays differences, pitfalls, and limitations
- Predictive/prognostic value of genomic and epigenomic BRCA alterations
- HR restoration and PARPi resistance
- BRCAness profile: PARPi sensitivity and resistance.
- Current and novel potential therapeutic strategies targeting DDR actors
- Turning HR proficient in HR deficient OC
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Topic Editor Dr. Umberto Malapelle has received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientific, Eli Lilly, Diaceutics, GSK, Merck and AstraZeneca, Janssen, Diatech, Novartis and Hedera unrelated to the current work. The Editor Dr. De Angelis has received personal fees (as consultant and/or speaker bureau) from Roche, MSD, Eli Lilly, GSK, AstraZeneca, Novartis, Pfizer, GILEAD and Daiichi Sankyo, and has received research grants (to Institution) from Novartis, GILEAD, and Daiichi Sankyo. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Keywords: Ovarian cancer, homologous recombination deficiency (HRD), DNA damage response (DDR), Homologous recombination repair (HRR), poly (ADP-ribose) polymerase inhibitor (PARPi), PARPi resistance, next-generation sequencing (NGS)
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.